Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Express Scripts
Baxter
Mallinckrodt
McKinsey

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,114,021

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,114,021
Title:Body-associated receiver and method
Abstract: Receivers, which may be external or implantable, are provided. Aspects of receivers of the invention include the presence of one or more of: a high power-low power module; an intermediary module; a power supply module configured to activate and deactivate one or more power supplies to a high power processing block; a serial peripheral interface bus connecting master and slave blocks; and a multi-purpose connector. Receivers of the invention may be configured to receive a conductively transmitted signal. Also provided are systems that include the receivers, as well as methods of using the same. Additionally systems and methods are disclosed for using a receiver for coordinating with dosage delivery systems.
Inventor(s): Robertson; Timothy (Belmont, CA), Omidvar; Fataneh (Danville, CA), Behzadi; Yashar (San Francisco, CA), Arne; Lawrence (Redwood City, CA), Rowberry; Kenneth (San Jose, CA), Hutchison; James (Palo Alto, CA), Leichner; Robert (Menlo Park, CA), Savage; George (Portola Valley, CA), Thompson; Andrew (Portola Valley, CA), Zdeblick; Mark (Portola Valley, CA), Kreidler; Marc (Sunnyvale, CA), Hafezi; Hooman (Redwood City, CA), Duck; Robert (San Francisco, CA)
Assignee: Proteus Biomedical, Inc. (Redwood City, CA)
Application Number:12/673,326
Patent Claim Types:
see list of patent claims
Delivery; Device;

Drugs Protected by US Patent 8,114,021

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-001 Nov 13, 2017 RX Yes No   Request a Trial   Request a Trial Y   Request a Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-002 Nov 13, 2017 RX Yes Yes   Request a Trial   Request a Trial Y   Request a Trial
Otsuka Pharm Co Ltd ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202-003 Nov 13, 2017 RX Yes No   Request a Trial   Request a Trial Y   Request a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,114,021

PCT Information
PCT FiledDecember 15, 2009PCT Application Number:PCT/US2009/068128
PCT Publication Date:July 01, 2010PCT Publication Number: WO2010/075115

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Mallinckrodt
Dow
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.